Science and Innovation

Scientists around the world have been mapping the cannabis plant and cataloging its compounds, eager to gain a deeper understanding of how they exert their effects and to harness their immense therapeutic potential. Promising though this research may be, the cannabis plant itself is prohibited for use almost everywhere in the world. Even with laws aside, cannabis is a difficult species to study. It is prone to mutation, an attribute that growers have exploited to produce hundreds of different strains, each of which has its own unique profile. Some are dominated by THC, and others by CBD, with numerous other cannabinoids in hugely different proportions. Even when isolated, standardizing individual cannabinoids is difficult.

In order to realize the therapeutic potential of these compounds, they must be available to scientists in a pure and consistent form to allow for rigorous, replicable research. Through collaboration with physicians, practitioners and scientists both across the U.S. and internationally, DiolPure is working to discover cannabinoid-based medicines.

Research Advantages

DiolPure has opened the door to a host of new possibilities for CBD and other cannabinoid-based therapeutics by working with proprietary, semi-synthetic, non-cannabis-derived, bioidentical cannabinoids.

Using its proprietary cannabinoids, DiolPure can achieve consistent dosing, time after time, reproducing results in any part of the world. This means our research always meets the rigorous requirements of truly viable medical discoveries. In addition, the crystal structure of these cannabinoids allows increased solubility and bioavailability, providing greater potential for a variety of drug delivery methods.

The natural products library unlocks possibilities for combining cannabinoids in ways that never occur in nature, and which may be the key to truley revolutionary therapeutics.

Strategic advantages of Diolpure over plant- extracted cannabinoids

Highly consistent, pharmaceutical grade compounds with the quality control, international standardization, and purity required for clinical research and replication at multiple sites.

Opportunity to obtain intellectual property around non-orphan indications; not limited by IP restrictions facing plant-extracted compounds.

Access to major and minor cannabinoids with therapeutic potential beyond cannabidiol (CBD).

All other cannabinoid research is limited by working with inconsistent plant extracts and chemically impure distillates, resulting in questionable science. By contrast, DiolPure works entirely with PureForm’s, semi-synthetic, bioidentical cannabinoids. These compounds have a unique crystalline structure and industry-leading purity profile, without impurities such as pesticides, mycotoxins, and psychoactive components, including THC, which can be found in plant-derived formulations.